01—Abstract
Summary
Summary of the 10-Q filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.
GE HealthCare Technologies Inc. (GEHC) reported a solid third quarter for 2024, with total revenues reaching $4.86 billiona, a 1% increase both on a reported and organic basis compared to the prior year.
This growth was driven by a 2% increase in service revenues and a slight uptick in product sales, despite challenges in the China market due to an ongoing anti-corruption campaign and delayed stimulus program. Operating income saw a significant increase of 10% to $676 millionb, and net income attributable to GE HealthCare common stockholders rose by 25% to $470 million, reflecting strong cost productivity and favorable pricing. The company also demonstrated robust cash flow generation, with operating cash flow of $1.04 billion for the nine-month period.
Financially, GEHC maintained a strong balance sheet with $3.57 billionc in cash, cash equivalents, and restricted cash as of September 30, 2024. The company successfully issued $1 billion in senior unsecured notes, strengthening its liquidity position.
Remaining Performance Obligations (RPO) stood at $14.56 billiond, indicating a healthy future revenue pipeline, though slightly down 1% from the end of 2023. The company's strategic acquisitions, such as MIM Software, are being integrated, and management remains optimistic about long-term growth prospects, particularly in expanding healthcare access globally.
02—Key points
Key Highlights
- Total revenues grew 1% to $4.86 billion for Q3 2024, with organic revenue also increasing by 1%.
- Operating income increased by 10% to $676 million, with operating margin improving by 110 basis points to 13.9%.
- Net income attributable to GE HealthCare common stockholders increased by 25% to $470 million, reflecting strong operational execution and cost management.
- The company successfully issued $1 billion in senior unsecured notes, bolstering its liquidity and managing its debt profile.
- Remaining Performance Obligations (RPO) stood at $14.56 billion as of September 30, 2024, providing visibility into future revenue.
- Acquisition of MIM Software for approximately $259 million was completed, adding AI solutions to the Imaging segment.
- Despite challenges in China, the Pharmaceutical Diagnostics (PDx) segment showed strong growth of 6% in Q3 2024, driven by volume, price increases, and new product introductions.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, GE HealthCare Technologies Inc. kept $0.10.
- Revenue$4.86B100.0%
- Cost of revenue−$2.84B58.3%
- Gross profit$2.03B41.7%
- Operating costs−$1.35B27.8%
- Operating income$676.0M13.9%
- Interest, other & tax−$206.0M4.2%
- Net income$470.0M9.7%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 30, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $4.86B$4.82B | +0.9% |
| Gross Profit | $2.03B$1.94B | +4.7% |
| R&D Expenses | $316.00M$322.00M | −1.9% |
| SG&A Expenses | $1.03B$996.00M | +3.8% |
| Operating Expenses | $1.35B$1.32B | +2.4% |
| Operating Income | $676.00M$617.00M | +9.6% |
| Net Income | $470.00M$375.00M | +25.3% |
| EPS (Basic) | $1.03$0.82 | +25.6% |
| EPS (Diluted) | $1.02$0.82 | +24.4% |
| Shares Outstanding (Basic) | 457.00M455.00M | +0.4% |
| Shares Outstanding (Diluted) | 459.00M458.00M | +0.2% |
05—Questions
Frequently Asked Questions
What was the overall revenue performance for GE HealthCare in Q3 2024?
GE HealthCare reported total revenues of $4.86 billion for the three months ended September 30, 2024, representing a 1% increase both on a reported and organic basis compared to the same period in the prior year. This growth was driven by a 2% increase in service revenues and a modest increase in product sales.
How did the company's profitability evolve in Q3 2024?
Profitability improved significantly. Operating income increased by 10% to $676 million, and operating margin expanded by 110 basis points to 13.9%. Net income attributable to GE HealthCare common stockholders grew by 25% to $470 million, driven by cost productivity, favorable pricing, and effective cost management across product and service lines.
What is the company's current liquidity position and how has its debt been managed?
GE HealthCare maintains a strong liquidity position with $3.57 billion in cash, cash equivalents, and restricted cash as of September 30, 2024. The company proactively managed its debt by issuing $1 billion in senior unsecured notes in Q3 2024, which will be used to repay an upcoming maturity. Total borrowings increased to $10.31 billion from $9.44 billion at the end of 2023.
What is the outlook for future revenue based on the company's order backlog?
The company's Remaining Performance Obligations (RPO) stood at $14.56 billion as of September 30, 2024. While this represents a slight decrease of 1% from the end of 2023, it still indicates a substantial future revenue pipeline, with product-related RPO largely expected to be recognized within two years and service-related RPO over a longer horizon.
06—Continue